Navigation Links
MAP Pharmaceuticals to Present at the 2008 RBC Capital Markets Healthcare Conference
Date:12/3/2008

MOUNTAIN VIEW, Calif., Dec. 3 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the company, will participate in a panel discussion titled "Adapting Specialty Pharma Strategy To Market Conditions" at the 2008 RBC Capital Markets Healthcare Conference on Wednesday, December 10, 2008, at 10:00 am (ET) in New York City.

A live webcast of the panel discussion will be available on the Investor Relations section of MAP Pharmaceuticals' website at http://www.mappharma.com. A replay will also be available within 24 hours for seven days following the presentation.

About MAP Pharmaceuticals, Inc.

MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for children and adults suffering from chronic conditions that are not adequately treated by currently available medicines. The company has two product candidates in Phase 3 clinical trials. Unit Dose Budesonide is being developed for the potential treatment of pediatric asthma, and MAP0004 is being developed for the potential treatment of migraine. MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk, by capitalizing on their known safety, efficacy and history.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.


'/>"/>
SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. The Westaim Corporation requisitions meeting of shareholders of NUCRYST Pharmaceuticals to return capital to NUCRYST shareholders
2. Quark Pharmaceuticals to Present at the 20th Annual Piper Jaffray Health Care Conference
3. Transcept Pharmaceuticals to Participate on Drug Delivery Investor Panel
4. China West II Files Suit Against Genesis Pharmaceuticals and Capital Research Group Inc, Announces Conference Call Details
5. Watson Pharmaceuticals Receives FDA Final Approval for Generic Wellbutrin XL(R) 150 mg
6. Idenix Pharmaceuticals to Present at the PiperJaffray 20th Annual Health Care Conference
7. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
8. Arena Pharmaceuticals to Present at the Piper Jaffray 20th Annual Health Care Conference
9. Roche Signs Definitive Agreement to Acquire Memory Pharmaceuticals
10. Transcept Pharmaceuticals, Inc. to Present at the 20th Annual Piper Jaffray Health Care Conference
11. King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2009)...ewswire/ -- The following is an investment opinion..., Inc. ,, Intellivest Securities Research, Inc.... has published a Report on BioClinica, Inc. ( BIOC...otechnology and medical device industries. A prim...ss and submit medical imaging portions of their su...
(Date:11/29/2009)...teach doctors-in-training how to do ultrasound-gui...r skills without compromising patient care and saf...ital. , The study shows that this simulation-bas...ve medical residents, knowledge, dexterity and con...rasound-guided procedures, including breast biopsi...
(Date:11/29/2009).... 29 Acuo Technologies, developers...ware, data migration tools and services, today ann...t allows image sharing across the networks of hosp...re solution is based on the versatile Acuo Technol...AcuoShare enables secure access from various PACS ...
(Date:11/29/2009)...treatment equals a $41,000 pay raise, researchers ...s) -- Psychological therapy may be much more effec...r winning a lottery prize, suggests an English stu... people who provided information about their menta...ess from a $1,329 course of therapy was so signifi...
(Date:11/29/2009)...e YogaForce A-Line Athletic Mat is great. It,s a ..., author and physician best known for establishing...e. Go to www.yogaforce.com and order the new Ma..., San Francisco, CA (PRWEB...ys, the YogaForce newly patented, revolutionary A-...
Breaking Medicine News(10 mins):Health News:Research Report on BioClinica, Inc. as Speculative Buy 2Health News:Simulated training for ultrasound-guided procedures improves safety without risk to patients 2Health News:Acuo Technologies Announces a New Offering That Enables Sharing of Imaging Studies Securely and Affordably 2Health News:Psychotherapy Can Boost Happiness More Than Money: Study 2Health News:The YogaForce A-Line Mat Provides The Perfect Solution For Fitness Needs 2Health News:The YogaForce A-Line Mat Provides The Perfect Solution For Fitness Needs 3
... Chairman and Managing Director of Eli Lilly and C...nouncement of a price cut in the company's human i...in product 'Iletin' will be phased out from the ma...f animal insulin products by other drug companies ...
... new generation mums are being plagued by a new ty...y mums. Experts say that though celebrity mums lik...nancy more sexy with cropped tops and clingy dress...o to diet while pregnant, putting their own and th...
...upplemental new drug application (sNDA) for Valtre...the U.S. Food and Drug Administration (FDA) for th...was announced by GlaxoSmithKline which also added ... Cold sores, also known as herpes labialis an...
...article published in an online issue of Nature Med...has reported a stunning discovery of a bold new ty...eir AIDS drugs. The study which was carried// out ...eported that the new vaccine uses a type of cell, ...
...ew study which appeared in the General Dentistry j...right light, loud noise, itchy clothes and strong ...This means// that such a person is likely to avoid...ring, taste and touch, with a notable finding that...
... foundation of diabetics care is the regular monit...many patients do not adhere to this routine becaus... multiple blood samples to be taken by puncturing/... which will end the pain of pricking for diabetes ...
Other Medicine News:
(Date:11/29/2009)..., , CHICAGO, Nov. 29 Resear...(fMRI) to study brain activation have found that m...egative stimuli, according to a study presented to...ety of North America (RSNA). ,, "Men may direct...imuli and tend to process them in terms of implica...
(Date:11/27/2009)..., , Another option to prevent illness..., SILVER SPRING, Md., Nov. 27 /PRNewswire-USNews...ay approved Agriflu for people ages 18 years and o...subtypes A and B. ,, (Logo: http://www.newsc...lu, manufactured by Novartis Vaccines and Diagnost...
(Date:11/27/2009)..., , BLOOMINGTON, Minn, Nov. 27 /PRNewswire/ ...ce medical image management software, data migrati... the United States Patent and Trademark Office has...nication Format within a Computer Network." Acuo T...ts portfolio of intellectual property. In general,...
Breaking Medicine Technology:New Study Finds Men and Women May Respond Differently to Danger 2New Study Finds Men and Women May Respond Differently to Danger 3FDA Approves Agriflu Seasonal Influenza Vaccine 2Acuo Technologies Announces Patent for Asset Communication Format Within a Computer Network 2Resident physicians seldom trained in skin cancer examination 59762 1Resident physicians seldom trained in skin cancer examination 59762 2GSA showcases groundbreaking aging research slated for Atlanta meeting 59757 1GSA showcases groundbreaking aging research slated for Atlanta meeting 59757 2GSA showcases groundbreaking aging research slated for Atlanta meeting 59757 3GSA showcases groundbreaking aging research slated for Atlanta meeting 59757 4UD to host conference on Ethics of Climate Change 10413 1UD to host conference on Ethics of Climate Change 10413 2
... Rigel,Pharmaceuticals, Inc. (Nasdaq: RIGL ) anno...n a Phase 1 study to evaluate the safety and,toler...itor of Janus Kinase,3 (JAK3), as a potential trea... psoriasis and other immune disorders. In preclini...ucing arthritic symptoms, bone destruction,and swe...
...SportsCoatings,today announced approximately 10 mi...d with its industry-leading antimicrobial coating,...e feet in 2007., The exponential increase in dema...tors, including a 2007 report in the Journal of th...thicillin-resistant Staphlycoccus,aureas) is respo...
Other Medicine Technology:Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders 2Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders 310 Million Square Feet of Turf Set to be Treated in 2008 in Response to MRSA Outbreaks Nationwide 2
Array Multifocal IOL
MEASLES (Rubeola) IgG IFA TEST
Captia Measles IgM
Measles (Rubeola) IgM ELISA
Medicine Products: